Consultation is now open for applications that are anticipated to be considered by the Medical Services Advisory Committee (MSAC) on 4-5 April 2024.
MSAC values consultation input from individuals and organisations with an interest in an application that it is considering, including experience of the medical conditions, services or technologies being addressed by the application.
It is anticipated that the below-mentioned applications will proceed to MSAC in April 2024. Consultation input must be received by no later than Friday, 16 February 2024 for it to be considered by MSAC. A consultation survey form is available on the relevant application webpage.
Further information on MSAC’s consultation process is also available on the MSAC website.
Applications scheduled to be considered:
1677.1 - Pharmacy Diabetes Screening Trial (PDST)
1686.1 - 177 Lutetium PSMA i&t for metastatic castrate resistant prostate cancer
1713 - Cardiac MRI in the diagnosis of myocarditis
1720 - 68Ga PSMA-11 PET/CT imaging for patients who are candidates for PSMA targeted therapy
1722.1 - Axicabtagene ciloleucel (YESCARTA®) for relapsed or refractory large B-cell lymphoma
1741 - Continuous Nerve Blockade using a catheter technique
1749 – Insertion of durable ventricular assist device (VAD) for use as destination therapy
To provide input on any of the applications listed, please click on the relevant application link above this box. This will take you to the relevant MSAC webpage where you will be able to download and complete a consultation survey.
Alternatively, you can provide a separate file with your input to commentsMSAC@health.gov.au
Guidance on what sort of information to include in your consultation input can be found on the MSAC website.
Consumers and consumer groups and organisations are welcome to contact the Consumer Evidence and Engagement Unit for questions on current consultations htaconsumerengagement@health.gov.au
Share
Share on Twitter Share on Facebook